Çakar, Esra
Oniangue-Ndza, César
Schneider, Ralph P.
Klijn, Sven L.
Vogl, Ursula M.
Rothermundt, Christian
May, Jessica R.
Funding for this research was provided by:
Bristol Myers Squibb
Article History
Accepted: 24 January 2023
First Online: 9 February 2023
Declarations
:
: This study was funded by BMS.
: Esra Çakar reports funding (institutional) from BMS to write this manuscript. Ursula M. Vogl reports honoraria (institutional) from Merck, BMS, Merck Sharp & Dohme (MSD), Pfizer, Janssen, Astellas, Roche, Bayer, Ipsen, and Sanofi, and (personal) from the Swiss Academy of Multidisciplinary Oncology (SAMO), Inselspital Bern, and Healthbook; payment for expert testimony (institutional) from Merck; travel support from Merck and Ipsen; and advisory board fees from Merck, BMS, MSD, Pfizer, Janssen, Astellas, Roche, Bayer, Ipsen, and Sanofi. Christian Rothermundt reports consulting fees from Merck (Schweiz) AG (personal) and Pfizer, BMS, MSD Oncology, Bayer (Schweiz) AG, and Ipsen (institutional). Sven L. Klijn reports consulting fees (institutional) from Bayer, BMS, Kite, and Janssen. César Oniangue-ndza, Ralph P. Schneider, and Jessica R. May are employed by and have stock ownership in BMS.
: Not applicable.
: Not applicable.
: Not applicable.
: BMS’s policy on data sharing may be found at ExternalRef removed.
: Not available. Code is intellectual property of OPEN Health.
: Conception and design: CO, RPS, SLK and JRM. Data acquisition: EÇ, UMV and CR. Data analysis: EÇ and SLK. Data interpretation: EÇ, CO, RPS, SLK, UMV, CR and JRM. Writing of the manuscript: EÇ, CO, RPS, SLK, UMV, CR and JMR.